SNDX Q4 2024 Earnings — Syndax Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

SNDXSyndax Pharmaceuticals, Inc.

$2B

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$8M

Gross Profit

$8M100.0% margin

Operating Income

-$96M-1254.8% margin

Net Income

-$94M-1226.2% margin

EPS (Diluted)

$-1.10

QoQ Revenue Growth

-38.6%

Cash Flow

Operating Cash Flow

-$57M

Free Cash Flow

-$57M

Stock-Based Comp.

$12M

Balance Sheet

Total Assets

$725M

Total Liabilities

$437M

Stockholders' Equity

$288M

Cash & Equivalents

$154M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$8M	$0	—
Gross Profit	$8M	$0	—
Operating Income	-$96M	-$78M	-23.7%
Net Income	-$94M	-$72M	-29.9%